Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.7 USD | +1.18% | -5.64% | -12.20% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
Evolution of the average Target Price on MiMedx Group, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering MiMedx Group, Inc.
Lake Street | |
Mizuho Securities | |
HC Wainwright | |
Northland Securities |
EPS Revisions
- Stock
- Equities
- Stock MiMedx Group, Inc. - Nasdaq
- Consensus MiMedx Group, Inc.